Immuron
- Short interest
- 0.14%
- +0.12 pp 30d
- as of 21 July 2025
- Reported shorts
- 380K
- Shares on issue
- 268.220M
Immuron (IMC) Short Interest
Immuron (ASX:IMC) had 0.14% of shares reported as short positions as of 21 July 2025, representing 380,000 shares. Immuron operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Immuron
Immuron is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapy treatments. Their proprietary technology platform utilizes dairy-derived polyclonal antibodies to address unmet medical needs in gastrointestinal health, liver diseases, and infectious diseases. Immuron's products aim to reduce diarrhea, enhance gut health, and promote immune defense.
Company profile →Immuron (ASX:IMC) has 0.14% of its shares on issue reported as short positions as of 21 July 2025, or about 380,000 shares. Over the past 30 days that figure has risen 0.12 percentage points, and over 90 days it has risen 0.12 percentage points. IMC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads IMC today
- Zanger BreakoutNot a candidate
- CAN SLIMWatchScore 15rank 859 of 1541
- Minervini Trend TemplateWatchScore 32rank 521 of 1716
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 18rank 827 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
IMC fundamentals
In the year to 30 Jun 2026, Immuron (ASX:IMC) recorded revenue of A$7.7M and a net loss after tax of A$3.7M. A year earlier it recorded revenue of A$7.3M and a net loss after tax of A$5.2M. Year-on-year growth: revenue +5.9% (FY). Net margin −47.7% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest IMC news
All news- Travelan Phase 2 Study Results Published
asx · 12 Oct 2026
- Immuron (ASX:IMC) Advances IMM-529 Partnering Strategy with Triple-Action CDI Approach
kalkine · 7 Oct 2026
- Change in substantial holding
asx · 30 Sept 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IMC
Start a research thread or post the first pulse update